The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Advances in RSV vaccine research and development – A global agenda
Open accessAbstract
• RSV is a significant annual cause of lower respiratory tract illness globally. • Pediatric and elderly populations are most vulnerable, but no vaccine exists. • The current state of RSV vaccine research and development is summarized. • 60 RSV vaccine candidates in development, of which 16 are in Phase 1–3 trials. Respiratory syncytial virus (RSV) is an important cause of viral lower respiratory tract illness in infants and children globally, but no vaccine is currently available to protect these vulnerable populations. Live-attenuated vaccine approaches have been in development for decades, but achieving the appropriate balance between immunogenicity and safety has proven difficult. Immunoprophylaxis with the neutralizing monoclonal antibody palivizumab is limited to high-risk infants, but cost requirements for multiple dosing make its use impractical in low- and middle-income countries. A growing number of RSV vaccine candidates using a variety of technologies and targeting diverse populations has emerged in recent years. There are now 60 RSV vaccine candidates in development that target pediatric and elderly populations. While most are at a preclinical stage, 16 candidates are in clinical development. This review summarizes current RSV vaccine research and development, including an overview of the vaccine platforms being used, the development stage of individual vaccine candidates, and gaps to be addressed to facilitate use of these vaccines to meet global health needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60206-1 · Cited by 2,773 · cited 2×
“A reduction in the incidence and severity of RSV-related ALRI in hildren younger than five years of age through vaccination in lownd middle-income countries (LMICs) would directly work toward eaching the fourth Millennium Development Goal of reducing hild mortality [5].”
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Groothuis, J. R., Simoes, E., Levin, M. J., Hall, C. B., Long, C. E., Rodriguez, W. J., Arrobio, J., Meissner, H. C., Fulton, D. R., Welliver, R. C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292102 · Cited by 744
Viral and Bacterial Interactions in the Upper Respiratory Tract
Bosch, A. A. T. M., Biesbroek, G., Trzcinski, K., Sanders, E. A. M., & Bogaert, D. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003057 · Cited by 651
Prince, G. A., Horswood, R. L., & Chanock, R. M. (1985) · Journal of Virology · doi:10.1128/jvi.55.3.517-520.1985 · Cited by 245 · cited 1×
“In passive prophylaxis studies with RSV-IGIV in rodents and infants, high titers of serum neutralizing antibody correlated with protection of the lower respiratory tract.[27-29] Correlates of protection against severe disease in young infants may differ by type of vaccine used and will need to be evaluated in the cont…”
Background
Cited by
Immunosenescence and human vaccine immune responses
Crooke, S. N., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2019) · Immunity & Ageing · doi:10.1186/s12979-019-0164-9 · Cited by 530
Early-Life Origins of Chronic Obstructive Pulmonary Disease
Martinez, F. D. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1603287 · Cited by 473
Kherfan, T., & Sallam, M. (2023) · Vaccines · doi:10.3390/vaccines11081386 · Cited by 26
Metadata
- Authors
- Higgins, D., Trujillo, C., & Keech, C.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 34
- Issue
- 26
- Pages
- 2870-2875
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2343080710
- Cited by
- 202
- References
- 7
- FWCI
- 27.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in RSV vaccine research and development – A global agenda. https://app.cochat.ai/papers/10.1016/j.vaccine.2016.03.109
- The paper
- Higgins, D., Trujillo, C., & Keech, C. (2016). Advances in RSV vaccine research and development – A global agenda. Vaccine. https://doi.org/10.1016/j.vaccine.2016.03.109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.